New eye health supplement flies in

Butterflies Healthcare launches ‘more cost-effective’ version of Viteyes 2 Softgels

28 Jul 2016 by Robina Moss

Butterflies Healthcare Viteyes 2Butterflies Healthcare has launched a new version of the Viteyes 2 Softgels eye health supplement.

The supplement is formulated to be easy to swallow, with the latest version said to be more cost-effective by offering patients a three-month supply.

Still with a recommended dose of just two softgels a day, the new version contains the same formulation recommended in the Age-Related Eye Disease Study 2 (AREDS2) – lutein 10mg, zeaxanthin 2mg, vitamin C 500mg, Vitamin E 400IU, zinc 25mg and copper.

Viteyes 2 is said by the company to be one of the UK’s most widely prescribed macular health supplements as it is based on the renowned Age-Related Eye Disease Study, and its follow-up, AREDS2.

The new product was launched recently to coincide with Macular Week 2016 (27 June – 3 July).

“As with the current capsules, Viteyes 2 Softgels can be prescribed subject to local restrictions, or can be bought from opticians,” company co-founder and optometrist, James Sutton, told OT.

“We are delighted to be bringing this new product to the UK market,” he added. “Whether buying over the counter, or on prescription, it is still the most cost-effective AREDS2 formulation, so we would encourage everyone to give their patients the best chance and switch today.”

To support the launch, recommendation pads, practice posters and patient leaflets are available for practitioners, as well as educational leaflets on age-related macular degeneration and lifestyle.

Butterflies Healthcare recently won the Small Business of the Year category in the Cherwell Business Awards. Based in Banbury, the company was a finalist in the awards three years ago and returned this year having grown steadily stronger since then.

For more information, telephone 0845 838 6704, or visit the Butterflies Healthcare website.


Your comments

You must be logged in to join the discussion. Log in

Comments (0)